A Prospective Randomized Controlled Trial: Efficacy and Metabolomics of Urgent ERCP Pancreatic Duct Stenting in the Treatment of Acute Gallstone Pancreatitis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051363

Enrollment

Unknown

Registered

2021-09-21

Start date

2021-10-01

Completion date

Unknown

Last updated

2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pancreatitis

Interventions

Experimental group:Conservative treatment combined with ERCP pancreatic duct stents

Control group:Conservative treatment

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 70 years; 2.Onset time = 8 points or CRP >= 150 mg/L; 4.Meet the diagnostic criteria for acute biliary pancreatitis; 5.Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with acute cholangitis or biliary obstruction; 2.Patients who have undergone pancreatic surgery in the past; 3.Pregnant or lactating women; 4.Acute development stage of chronic pancreatitis; 5.Patients with severe heart, lung, liver, kidney, or mental illness that affect the treatment effect of acute pancreatitis or cannot cooperate with the operator (heart function> grade III, acute myocardial infarction, chronic kidney disease creatinine clearance rate <40ml/min, chronic obstructive pulmonary disease patients requiring long-term oxygen therapy, Child-Pugh Class C liver function of chronic liver disease, immune disease or immunosuppression status, dying patients); 6.Patients who cannot tolerate pancreatic duct stenting for various reasons (e.g., contrast agent allergy, severe fundus esophageal varices; Upper gastrointestinal obstruction, ulceration, bleeding, etc. Coagulation dysfunction or long-term oral anticoagulant drugs; Rejection by patients or family members, etc.); 7.Patients with malignant tumors of the biliary and pancreatic system affecting the treatment effect; 8.Patients with other diseases that require simultaneous surgical treatment.

Design outcomes

Primary

Measure	Time frame
Incidence of infectious pancreatic necrosis;Metabonomics;	—

Secondary

Measure	Time frame
Hospital stay;Daily changes in visual simulation of pain scores;Dosage of pain medication;Incidence of new complications;Mortality rate;Daily changes in sequential organ failure score;Oral feeding time;Application time of anti-pancreatin drugs;Intensive care unit hospital stay and underlying reasons;Expenses during treatment (within and outside the insurance);Changes in inspection indexs;	—

Countries

China

Contacts

Public ContactWang Zuozheng

General Hosptal of Ningxia Medical University

wangzuozheng2008@sina.com+86 13895009292

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026